Dr. Jimmy Hao is a partner in the Intellectual Property Department and a registered patent attorney. He represents companies in the biotech and pharmaceutical industries. Jimmy possesses an extensive scientific knowledge, a strong business sense, and a deep understanding of patent, copyright, trademark and trade secrets laws.
Jimmy focuses his practice on patent prosecution, infringement and validity studies, freedom-to-practice studies and design-around analyses. He provides a full range of patent law services to clients, including developing and managing their worldwide patent portfolios, assisting in patent matters and due diligence in connection with strategic alliance, technology transfer transactions & licensing, investment, merger, and acquisition.
He has provided legal representation to several notable business transactions, including:
- Alexion Pharmaceuticals Inc.’s acquisition of Synageva BioPharma Corp (valued at $8.4 billion)
- Humanwell Pharmaceutical Group Corp.’s acquisition of Epic Pharma (valued at $550 million)
- BMS’s acquisition of Amira Pharmaceuticals (valued at $475 million)
- Licensing and collaboration deals involving major universities and companies including the Rockefeller University, Merck and Puracap Pharmaceutical
With a doctoral degree in molecular and cell biology, Jimmy is experienced in patent cases involving molecular biology, developmental biology, stem cells, tissue engineering, immunology, antibodies, vaccines, CRISPR/Cas genome editing, CAR-T, anti-sense technology, RNAi, protein, gene and cell therapies, diagnosis or treatments for various disorders, genomics, proteomics, bioinformatics, chip-array technologies, biomaterials, drug discover, and herbal medicine. He has prosecuted thousands of patent applications nationally and internationally.
As a member of the China Practice, Jimmy assists individual and institutional clients from China in pharmaceutical and biotech, as well as other industries on their matters in various areas of law. He is equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients. Jimmy is frequently called upon to advise clients on IP issues and conduct IP due diligence in U.S./China cross-border transactions. He is frequently invited to speak on IP issues both in the United States and in China.
Before Fox Rothschild
Prior to joining Fox Rothschild, Jimmy was an associate at a boutique intellectual property firm. He was also a patent agent for five years at a leading international firm. Prior to his legal career, Jimmy conducted research on neural and heart development at Columbia University as a graduate student. During his time at Columbia University, Jimmy’s Ph.D. thesis was awarded With Distinction. He later held a postdoctoral fellowship at Harvard Medical School where he conducted research on oncology, immunology, stem cells and hematopoiesis. Jimmy also advised the business technology group of an international pharmaceutical company on integration issues while studying at the Johnson Graduate School of Management at Cornell University.
Beyond Fox Rothschild
Jimmy is the Chair of both the Board of Trustees for the Huaxia Chinese School and the Board of Trustees for the Huaxia Chinese School at Plainsboro. He is also a Board Member & Founder of BioKatalyst, a nonprofit organization of Chinese business leaders in commercial areas of biopharmaceutical industry in the United States and China.